| Psoriasis vulgaris
Tremfya vs Zoryve Foam
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Tremfya vs Zoryve with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZoryve has a higher rate of injection site reactions vs Tremfya based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zoryve but not Tremfya, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tremfya
Zoryve
At A Glance
Subcutaneous / Intravenous
Every 4-8 weeks
Interleukin-23 antagonist
Topical
Once daily
PDE4 inhibitor
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Ulcerative Colitis
- Crohn Disease
- Seborrheic dermatitis
- Psoriasis vulgaris
Dosing
Psoriasis vulgaris Adults: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter. Pediatric patients >=6 years and >=40 kg: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter.
Arthritis, Psoriatic Adults: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter, alone or with conventional DMARD. Pediatric patients >=6 years and >=40 kg: 100 mg subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter, alone or with conventional DMARD.
Ulcerative Colitis Induction: 200 mg intravenous infusion over at least one hour at Week 0, 4, and 8, or 400 mg subcutaneous injection at Week 0, 4, and 8. Maintenance: 100 mg subcutaneous injection at Week 16 and every 8 weeks thereafter, or 200 mg subcutaneous injection at Week 12 and every 4 weeks thereafter.
Crohn Disease Induction: 200 mg intravenous infusion over at least one hour at Week 0, 4, and 8, or 400 mg subcutaneous injection at Week 0, 4, and 8. Maintenance: 100 mg subcutaneous injection at Week 16 and every 8 weeks thereafter, or 200 mg subcutaneous injection at Week 12 and every 4 weeks thereafter.
Seborrheic dermatitis, Psoriasis vulgaris Apply a thin layer once daily to affected areas of body and/or scalp when not wet; rub in completely; for topical use only, not for ophthalmic, oral, or intravaginal use.
Contraindications
- History of serious hypersensitivity reaction to guselkumab or to any of the excipients
- Moderate to severe liver impairment (Child-Pugh B or C)
Adverse Reactions
Most common (>=1%) Upper respiratory infections (14.3%), headache (4.6%), injection site reactions (4.5%), arthralgia (2.7%), diarrhea (1.6%), gastroenteritis (1.3%), tinea infections (1.1%), herpes simplex infections (1.1%).
Serious Serious infections occurred in <=0.2% in plaque psoriasis trials through Week 16. In ulcerative colitis trials, serious infections occurred in 0.8% with TREMFYA vs. 0% with placebo (44-week trial) and 1.8% vs. 0.7% (24-week trial). In Crohn's disease, serious infections occurred in 1.5% with TREMFYA vs. 0% with placebo.
Postmarketing Hypersensitivity including anaphylaxis, rash.
Most common (>=1%) - Seborrheic dermatitis nasopharyngitis, nausea, headache
Most common (>=1%) - Psoriasis vulgaris headache, diarrhea, nausea, nasopharyngitis
Pharmacology
Guselkumab is a human monoclonal IgG1 lambda antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23) and inhibits its interaction with the IL-23 receptor, thereby inhibiting the release of proinflammatory cytokines and chemokines.
PDE4 inhibitor; roflumilast and its active N-oxide metabolite inhibit PDE4, a major cyclic AMP-metabolizing enzyme, leading to accumulation of intracellular cyclic AMP; the specific mechanism(s) by which roflumilast exerts its therapeutic action is not well defined.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tremfya
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
Zoryve
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Tremfya
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (5/8) · Qty limit (5/8)
Zoryve
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Tremfya
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Zoryve
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Psoriatic Arthritis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
$0
Arcutis Cares Patient Assistance: ZoryveCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TremfyaView full Tremfya profile
ZoryveView full Zoryve profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.